General documents

Documents issued by JPAC

These documents are issued by JPAC and/or its Standing Advisory Committees. A review system exists to ensure documents are regularly reviewed.

2022

March: Blood component request and code allocation process
March: Validation of dried plasma

2021

September: Specification for the future labelling of blood components prepared in the UK
March: Deviations from the specified storage temperature for Fresh Frozen Plasma (FFP) whilst in its frozen state

2019

November: Road map for UK Blood Services to manage a hepatitis A outbreak
March: Look Back and Trace Back
March: Validation of plasma and platelet pathogen inactivation
February: Trial-Provisional component specifications

2016

November: Deviations from 4°C temperature storage for red cells: Effect on viability and bacterial growth

2015

November: Options for Human T-Lymphotropic Virus (HTLV) screening with the UK Blood Services

2008

November: Recommendations for removal of the upper age limit for regular whole blood and component donors

2007

November: The Use of G-CSF in Unrelated Volunteer Stem Cell Donors

Documents relevant to the UK blood supply

These documents affect the Blood Transfusion and Tissue Transplantation Services in the UK but are not issued by JPAC.

While we make every effort to ensure the latest version of these documents are published, JPAC cannot guarantee that these documents are regularly reviewed nor that the latest version is published here.

Should you be aware of a more up-to-date version of a document, we would appreciate notification by contacting JPACOffice@nhsbt.nhs.uk.

FAIR (For the Assessment of Individualised Risk)

2022: FAIR III: Can the policy recommendations from FAIR be safely and effectively applied to tissue and cell donors across the UK?
2021: FAIR II: An assessment of the evidence for the donor selection question asking about sexual partners who may have had sex in areas of the world where HIV is very common
2020: FAIR I: Can donor selection policy move from a population-based donor selection policy to one based on a more individualised risk assessment?